1-20 of 44 results for subject:Streptococcus
Librarians' tools
- Search time
- 0.214 seconds
- Solr query time
- 0.005 seconds
- Search query
- subject:Streptococcus
- We searched for
- subject_t:Streptococcus OR subject_t:"Strep A" OR subject_t:"Streptococcal infections" OR subject_ses:368447
Type
House
Session
Year
Department
Member
Primary member
Answering member
Legislative stage
Legislation
Subject
Publisher
To ask the Secretary of State for Health how many babies were born with Group B streptococcus in each of the last five years.
To ask the Secretary of State for Health how many babies were born with Group B streptococcus in each of the last five years.
Public Health England (PHE) does not have data on the number of babies born each year with group B streptococcus (GBS) colonisation.
PHE does have surveillance data collected from routine laboratory reporting outlining the numbers of babies less than seven days old diagnosed with GBS bacteraemia (“early onset disease”).
Data supplied in the following table are the annual counts of GBS bacteraemia in babies with early onset disease in England, Wales and Northern Ireland; 2008 to 2012
| Area | 2008 | 2009 | 2010 | 2011 | 2012 |
| England | 262 | 246 | 271 | 260 | 251 |
| Northern
Ireland
(NI) | 11 | 11 | 17 | 6 | 11 |
| Wales | 6 | 10 | 14 | 15 | 8 |
| England,
Wales and
NI | 279 | 267 | 302 | 281 | 270 |
The early onset GBS bacteraemia data are published as part of the Health Protection Report series, the most recent streptococcal infection report was published in November 2013.
To ask the Secretary of State for Health what comparative assessment he has made of the effectiveness of the enriched culture medium and the general purpose test for testing Group B streptococcus in babies.
To ask the Secretary of State for Health what comparative assessment he has made of the effectiveness of the enriched culture medium and the general purpose test for testing Group B streptococcus in babies.
The chief medical officer requested the former Health Protection Agency (HPA) to explore whether a more accurate test for group B streptococcus (GBS) in pregnant women, called enriched culture medium (ECM), should be made available in its regional laboratories, when there was a clinical indication for testing.
In response to this, Public Health England (PHE, formerly the HPA) undertook a piece of work with clinical organisations to determine in which circumstances the ECM test could be used in pregnant women.
In the event, this work concluded that within current clinical guidance from the key professional bodies, UK National Screening Committee, the Royal College of Obstetricians and Gynaecologists and the National Institute for Health and Care Excellence, there are no clinical indications which should prompt the offer of an ECM test for GBS and so PHE decided not to provide this test in its laboratories.
PHE does not offer any testing exclusively for GBS in babies. When a neonate presents with symptoms consistent with a systemic infection—or sepsis—isolation of micro-organisms from blood cultures remains the gold standard method of diagnosing sepsis. Neonatal sepsis can be caused by GBS, but other important micro-organisms such as E.coli and Staphylococcus aureus can also cause sepsis, and blood culture is the most effective method of differentiating between these different types of bacteria.
To ask the Secretary of State for Health if he will make an assessment of the effectiveness of enriched culture medium testing in (a) France, (b) Canada, (c) Spain, (d) the US and (e) other countries to identify Group B streptococcus.
To ask the Secretary of State for Health if he will make an assessment of the effectiveness of enriched culture medium testing in (a) France, (b) Canada, (c) Spain, (d) the US and (e) other countries to identify Group B streptococcus.
Public Health England (PHE) understands that enriched culture medium (ECM) testing is available for women during pregnancy in some other countries including some European countries, the United States of America and Canada.
In the United Kingdom, the National Screening Committee (UK NSC) advises Ministers and the national health service in all four UK countries about all aspects of screening policy, including screening policy for group B streptococcus (GBS) carriage in pregnancy.
At its meeting in 2012 the UK NSC recommended that in the UK context, screening for GBS carriage at 35 to 37 weeks of pregnancy should not be offered. When reviewing the evidence for antenatal screening for GBS carriage, the UK NSC looked at evidence from a number of countries. A systematic review of the global prevalence of early and late onset GBS was reviewed. This suggested that the rate of infections in the UK was comparable to that in countries and regions employing widespread testing.
Within the English context, PHE undertook a piece of work with clinical organisations, including the Royal College of Obstetricians and Gynaecologists, to determine
whether there are any circumstances in which the ECM test could be applied within current accepted standards of care.
This work by PHE concluded that there are no clinical indications for testing women for GBS using ECM methods as recommended within current guidance from the key professional bodies.
To ask the Secretary of State for Health what his future plans are for introducing Enriched Culture Medium testing for Group B Strep.
To ask the Secretary of State for Health what his future plans are for introducing Enriched Culture Medium testing for Group B Strep.
There are currently no plans to introduce, the test because within current clinical guidance from the key professional bodies, the Royal College of Obstetricians and Gynaecologists or the National Institute for Health and Care Excellence, there are no clinical indications which should prompt the offer of an enriched culture medium test for group B streptococcus.
Should the clinical guidance change the situation would be reviewed.
To ask the Secretary of State for Health for what reasons Enriched Culture Medium testing for group B Strep (GBS) was not introduced on 1 January 2014; and who took such a decision.
To ask the Secretary of State for Health for what reasons Enriched Culture Medium testing for group B Strep (GBS) was not introduced on 1 January 2014; and who took such a decision.
The chief medical officer requested the former Health Protection Agency (HPA) to make recommendations for the introduction of a more accurate test for group B streptococcus (GBS) called enriched culture medium (ECM), and make it available in its regional laboratories when there was a clinical indication for testing.
In response to this, Public Health England (PHE, formerly the HPA) undertook a piece of work with clinical organisations, including the Royal College of Obstetricians and Gynaecologists, to determine whether there are any circumstances in which the ECM test could be applied within the current standard of care.
This work by PHE concluded in December 2013 that there are no clinical indications for testing women for GBS using ECM methods as recommended within current guidance from the key professional bodies, and therefore no indications which should prompt the offer of an ECM test.
The UK National Screening Committee also recommended in 2012 that a programme of universal screening of pregnant women at 35 weeks for GBS should not be established in the United Kingdom.
PHE therefore decided not to provide this test in its laboratories.
To ask the Secretary of State for Health what the reason was for his Department's decision not to introduce Enriched Culture Medium testing for Group B Strep on 1 January 2014. despite Ministers' previous commitment to do this; and who took that decision.
To ask the Secretary of State for Health what the reason was for his Department's decision not to introduce Enriched Culture Medium testing for Group B Strep on 1 January 2014. despite Ministers' previous commitment to do this; and who took that decision.
The chief medical officer requested the former Health Protection Agency (HPA) to make recommendations for the introduction of a more accurate test for group B streptococcus (GBS) called enriched culture medium (ECM), and make it available in its regional laboratories when there was a clinical indication for testing.
In response to this, Public Health England (PHE, formerly the HPA) undertook a piece of work with clinical organisations, including the Royal College of Obstetricians and Gynaecologists, to determine whether there are any circumstances in which the ECM test could be applied within the current standard of care.
This work by PHE concluded in December 2013 that there are no clinical indications for testing women for GBS using ECM methods as recommended within current guidance from the key professional bodies, and therefore no indications which should prompt the offer of an ECM test.
The UK National Screening Committee also recommended in 2012 that a programme of universal screening of pregnant women at 35 weeks for GBS should not be established in the United Kingdom.
To ask the Secretary of State for Health if he will publish the reply by the Acting Chief Executive of the Health Protection Agency to the letter sent to him on 21 December 2012 by the Chief Medical Officer, Department of Health, in respect of Group B streptococcus in intrapartum...
To ask the Secretary of State for Health if he will publish the reply by the Acting Chief Executive of the Health Protection Agency to the letter sent to him on 21 December 2012 by the Chief Medical Officer, Department of Health, in respect of Group B streptococcus in intrapartum...
The current Director for Health Protection and Medical Director for Public Health England (formerly the acting chief executive of the Health Protection Agency) is content to share the reply to the letter sent to him on 21 December 2012 by the chief medical officer, Department of Health, in respect of Group B streptococcus.
A copy of the letter has been placed in the Library.
To ask the Secretary of State for Health what advice his Department has given to regional and local laboratories to raise awareness among microbiology and pathology staff to ensure that the enhanced medium is offered when testing is requested in respect of Group B streptococcus in intrapartum women; and if...
To ask the Secretary of State for Health what advice his Department has given to regional and local laboratories to raise awareness among microbiology and pathology staff to ensure that the enhanced medium is offered when testing is requested in respect of Group B streptococcus in intrapartum women; and if...
Public Health England (PHE) published a briefing note in January 2014 to provide information for PHE's regional microbiologists on the appropriate place of enriched culture medium (ECM) testing within current United Kingdom guidelines. This document was developed following discussion with other relevant professional bodies and is available on their website.
The work that led to this briefing note concluded that no indications for testing high risk women using ECM methods have been evaluated or recommended within current clinical practice. Offering the test to low risk women at 35-37 weeks of pregnancy is also not recommended in the UK.
As a result of this work, PHE decided not to introduce the test within its laboratories.
This was also mentioned in internal PHE communications in December 2013 to regional heads of microbiology operations and regional microbiology network managers.
To ask the Secretary of State for Health when he expects Public Health England to make available the improved Enriched Culture Medium test for group B Strep carriage.
To ask the Secretary of State for Health when he expects Public Health England to make available the improved Enriched Culture Medium test for group B Strep carriage.
Public Health England investigated the circumstances in which the Enriched Culture Medium (ECM) test could be used within the current guidance set out in Royal College of Obstetrics and Gynaecology guidelines on the prevention of early onset neonatal Group B Streptococcus (GBS) disease. The outcome of this work concludes that there are currently no clinical indications for the test in high risk women using ECM methods within current guidance.
Research into the use of tests for GBS carriage in high risk clinical circumstances is being considered now with the National Institute of Health Research Health Technology Assessment programme.
Researchers stated:
“The most striking finding that has implications for clinical practice and policy is the low sensitivity of risk factor based screening, compared with PCR or culture tests in predicting maternal and neonatal GBS colonisation—”
Researchers stated:
“The most striking finding that has implications for clinical practice and policy is the low sensitivity of risk factor based screening, compared with PCR or culture tests in predicting maternal and neonatal GBS colonisation—”
I warmly commend my hon. Friend on bringing the issue before the House. I have a constituent who lost a child as a result of it, so it is something that I take seriously. Is my hon. Friend pleased, as I am, to see that Public Health England is now...
I warmly commend my hon. Friend on bringing the issue before the House. I have a constituent who lost a child as a result of it, so it is something that I take seriously. Is my hon. Friend pleased, as I am, to see that Public Health England is now...
I welcome my hon. Friend’s intervention, and I will go on to talk about the gold standard culture medium.
The researchers continued that the sensitivity of such screening was
“below that which we considered to be a minimally acceptable sensitivity for our study—which calls into question the validity of the current UK...
I welcome my hon. Friend’s intervention, and I will go on to talk about the gold standard culture medium.
The researchers continued that the sensitivity of such screening was
“below that which we considered to be a minimally acceptable sensitivity for our study—which calls into question the validity of the current UK...
I congratulate my hon. Friend the Member for Mid Bedfordshire (Nadine Dorries) on securing this debate and raising this very important issue. The death of a baby is devastating for parents and their families. It is important that we do all we can to minimise the risk of such deaths....
I congratulate my hon. Friend the Member for Mid Bedfordshire (Nadine Dorries) on securing this debate and raising this very important issue. The death of a baby is devastating for parents and their families. It is important that we do all we can to minimise the risk of such deaths....
For the reasons I highlighted, we know that the risk-based strategy is not working effectively. Does the Minister not agree that in countries that have routine testing the chances are greatly improved? He drew comparisons with the US, France and other countries, but we do not know what their figures...
For the reasons I highlighted, we know that the risk-based strategy is not working effectively. Does the Minister not agree that in countries that have routine testing the chances are greatly improved? He drew comparisons with the US, France and other countries, but we do not know what their figures...
I will come to those points a little later, but I will try to reassure my hon. Friend. Given that the majority of babies who die from group B strep are born prematurely, testing at 35 to 37 weeks would not benefit them. Tragically, they would have died in any...
I will come to those points a little later, but I will try to reassure my hon. Friend. Given that the majority of babies who die from group B strep are born prematurely, testing at 35 to 37 weeks would not benefit them. Tragically, they would have died in any...
That is encouraging news but again the focus is on women who are at risk of group B strep. I am advocating that all women should be tested for group B strep. I recommend that every pregnant woman I meet now buys a kit to test for group B strep....
That is encouraging news but again the focus is on women who are at risk of group B strep. I am advocating that all women should be tested for group B strep. I recommend that every pregnant woman I meet now buys a kit to test for group B strep....
I am hopeful that the audit by the RCOG nationally—something I discussed with the group B strep groups and the chief medical officer at a meeting this time last year to progress the work at a greater pace—will put us in a better position to understand in particular which women...
I am hopeful that the audit by the RCOG nationally—something I discussed with the group B strep groups and the chief medical officer at a meeting this time last year to progress the work at a greater pace—will put us in a better position to understand in particular which women...
Earlier, my hon. Friend said that some countries that screen have higher rates of group B strep than we do. Does he have any data—he could perhaps write to my hon. Friend the Member for Mid Bedfordshire (Nadine Dorries) and myself—to show what the progression has been since testing was...
Earlier, my hon. Friend said that some countries that screen have higher rates of group B strep than we do. Does he have any data—he could perhaps write to my hon. Friend the Member for Mid Bedfordshire (Nadine Dorries) and myself—to show what the progression has been since testing was...
I would be delighted to do so. It is important to consider the confounding factors that arise in any research. For example, there is some evidence of different rates of carriage of group B strep among different population groups. Also, the clinical treatment of the disease in hospitals—which is separate...
I would be delighted to do so. It is important to consider the confounding factors that arise in any research. For example, there is some evidence of different rates of carriage of group B strep among different population groups. Also, the clinical treatment of the disease in hospitals—which is separate...
I am interested in what the Minister has just said. As I mentioned in my speech, we are talking about a penicillin, a narrow-spectrum antibiotic. I know the Minister’s background, and he will know that GPs would prescribe it for a throat infection. This is a widely and commonly used...
I am interested in what the Minister has just said. As I mentioned in my speech, we are talking about a penicillin, a narrow-spectrum antibiotic. I know the Minister’s background, and he will know that GPs would prescribe it for a throat infection. This is a widely and commonly used...